Files and links (2)
Cannabis sativa - Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC2.30 MB
Published VersionCC BY V4.0, Open Access
Journal article
Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
Biomedicines, Vol.9(3), pp.1-42
2021
PMID: 33652704
Abstract
Cannabis sativa (Cannabis) is one of the world's most well-known, yet maligned plant species. However, significant recent research is starting to unveil the potential of Cannabis to produce secondary compounds that may offer a suite of medical benefits, elevating this unique plant species from its illicit narcotic status into a genuine biopharmaceutical. This review summarises the lengthy history of Cannabis and details the molecular pathways that underpin the production of key secondary metabolites that may confer medical efficacy. We also provide an up-to-date summary of the molecular targets and potential of the relatively unknown minor compounds offered by the Cannabis plant. Furthermore, we detail the recent advances in plant science, as well as synthetic biology, and the pharmacology surrounding Cannabis. Given the relative infancy of Cannabis research, we go on to highlight the parallels to previous research conducted in another medically relevant and versatile plant, Papaver somniferum (opium poppy), as an indicator of the possible future direction of Cannabis plant biology. Overall, this review highlights the future directions of cannabis research outside of the medical biology aspects of its well-characterised constituents and explores additional avenues for the potential improvement of the medical potential of the Cannabis plant.
Details
- Title
- Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
- Authors
- Jackson M J Oultram (Author) - University of Newcastle AustraliaJoseph L Pegler (Author) - University of Newcastle AustraliaTimothy A. Bowser (Author) - CannaPacific Pty. Ltd.Luke J. Ney (Author) - University of TasmaniaAndrew Eamens (Author) - University of Newcastle AustraliaChristopher P L Grof (Author) - University of Newcastle Australia
- Publication details
- Biomedicines, Vol.9(3), pp.1-42
- Publisher
- MDPI AG
- Date published
- 2021
- DOI
- 10.3390/biomedicines9030234
- ISSN
- 2227-9059
- PMID
- 33652704
- Copyright note
- Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- Organisation Unit
- School of Health - Biomedicine; University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy
- Language
- English
- Record Identifier
- 99656593702621
- Output Type
- Journal article
Metrics
19 File views/ downloads
13 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Biochemistry & Molecular Biology
- Medicine, Research & Experimental
- Pharmacology & Pharmacy
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites